Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in eosinophilic COPD with frequent exacerbations
jRCT2031250456Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of lunsekimig in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Sanofi. Primary endpoint: Annualized rate of moderate-to-severe COPD exacerbations. Started Nov 2025; status: recruiting.
02
Drugs
lunsekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031250456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250456.